https://www.prnewswire.com/news-releases/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline-302652998.html
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the...
dark blueamgenacquirestherapeuticsoncology
https://www.onward-therapeutics.com/
Onward Therapeutics is a development stage oncology company, focusing on the identification of innovative technologies and the development of truly...
oncologyonwardtherapeutics
https://springworkstx.com/
Oct 22, 2025 - We relentlessly pursue every possibility to create new cancer breakthroughs and power our approach with people who think hard, care hard, and act with urgency....
springworks therapeuticsunlockingtargetedoncology
https://www.businesswire.com/news/home/20201026005156/en/Scorpion-Therapeutics-Launches-with-%24108-Million-to-Advance-Precision-Oncology-2.0
Scorpion Therapeutics, Inc. today announced the closing of a $108 million Series A financing.
precision oncologyscorpiontherapeuticslaunchesmillion
https://www.jubilanttx.com/
As a patient-centric biopharmaceutical company, Jubilant Therapeutics leverages innovation to address unmet medical needs in oncology and autoimmune diseases.
jubilanttherapeuticsoncologyautoimmune
https://www.home.saxo/pl-pl/markets/stocks/bbot-xnas
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of...
oncology therapeuticssaxo bankbridgebioincakcja
https://www.macrotrends.net/stocks/charts/BBOT/bridgebio-oncology-therapeutics/gross-margin
Current and historical gross margin for BridgeBio Oncology Therapeutics (BBOT) over the last 10 years. The current gross profit margin for BridgeBio Oncology...
oncology therapeuticsgross marginbridgebiobbotmacrotrends
https://www.newswire.com/news/oncology-pharma-licensor-and-co-development-partner-kalos-therapeutics-21133200
Oncology Pharma Inc. (OTCPK:ONPH) is pleased to announce further information from its Licensor, Kalos Therapeutics
development partneroncologypharmalicensorkalos
https://www.biospace.com/hox-therapeutics-and-vernalis-announce-a-drug-discovery-collaboration-in-oncology
Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned...
drug discoveryhoxtherapeuticsvernalisannounce
https://www.globenewswire.com/news-release/2024/05/02/2874030/0/en/BridgeBio-launches-BridgeBio-Oncology-Therapeutics-BBOT-with-200M-of-private-external-capital-to-accelerate-the-development-of-its-novel-precision-oncology-pipeline.html
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV...
oncology therapeuticsbridgebiolaunchesbbot